Stock Analysis on Net

Cigna Group (NYSE:CI)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 27, 2025.

Analysis of Inventory

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Inventory Disclosure

Cigna Group, balance sheet: inventory

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Prescription drugs and medical supplies
Inventories

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Trend Analysis of Prescription Drugs and Medical Supplies / Inventories

The data exhibits a consistent upward trend in the value of prescription drugs and medical supplies, which is identical to the inventories value over the analyzed period from 2020 to 2024.

Starting at US$3,165 million in 2020, the value increased to US$3,722 million in 2021, representing a growth of approximately 17.6%. The upward trend accelerated in subsequent years, reaching US$4,777 million in 2022, a significant rise of about 28.4% from the previous year.

In 2023, a further increase to US$5,645 million was recorded, reflecting a growth rate of around 18.2%, while the latest figure for 2024 shows continued expansion to US$6,692 million, which is an 18.5% increase compared to 2023.

Overall, the data indicates strong and steady growth in the inventories, specifically prescription drugs and medical supplies, over the five-year period. The consistent rise suggests increasing investment or accumulation in these assets, potentially aligned with business expansion, rising demand, or strategic stockpiling.